Director/ Associate Director, Bioinformatics
Codiak is the leader in the emerging field of exosome therapeutics, working to harness the power of this cellular messenger system to create potentially life-changing medicines. A venture-backed startup founded in 2015, Codiak has rapidly built a proprietary technology platform for exosome engineering and manufacturing that allows for precise targeting of important molecular pathways, opening the door to the development of therapies for cancer and other diseases. Led by an experienced and dedicated team, Codiak has at its foundation a positive and collaborative culture that is deeply rooted in cutting edge science and promotes opportunity for growth.
Provide scientific input and leadership to enable the team to analyze complex data, including but not limited to genomic, Proteomics data, and lead the team to develop novel predictive models by integrating internal data sets with publicly available ‘Omics data using statistical techniques and state of the art bioinformatics tools to enable a better patient stratification and biomarker selections in clinical trials and identify novel exosome biology. This will be a visible leadership position in the organization with an ability establish and lead the bioinformatics function within the organization.
- • Provide immediate support to lead programs by leveraging internal datasets to perform integrated analysis of data from multiple platforms (Genomic, Proteomics platforms, etc.) to inform clinical studies.
- • Ability to adapt latest scientific findings and methods into bioinformatics analysis plans to analyze large-scale omics datasets (genomics/proteomics) including RNASeq, Nanostring and qPCR
- • Interface with exploratory research, clinical development group, to develop a computational analysis plan that will allow exploratory biomarkers inform clinical development.
- • Provide high level understanding of computational analysis for biomarker development for patient stratification/enrichment and provide potential models for patient responder-non-responder analysis.
- • The development of data analysis guidance, standards, workflow, software applications, and data warehouses to improve the analysis practice, visualization, integration, and accessibility to the complex clinical data.
- • Execute the data analysis plan and present actionable results to enable the company to meet its regulatory, scientific and business objectives.
- • Ensure scientific integrity, analysis pipeline validation, and regulatory compliance.
- • Lead and initiate both internal and external collaborations in large-scale clinical data analysis to support corporate long-term development goals.
- • Serve as an internal expert in machine learning, predictive modeling, and quantitative data analysis.
- • Leverage both internal and external resources to provide for analytic needs and clarify resourcing plans.
- • PhD. in statistics, mathematics, bioinformatics, computational biology, genomics, computer science, or a related field with 8+ years of experience in the pharmaceutical industry focus on quantitative data analysis.
- • Demonstrated experience working with Clinical study data required with deep understanding of disease biology in immunology including auto-immunity and inflammatory disease strongly preferred.
- • Ability to work independently and collaboratively to handle several concurrent fast-paced projects required.
- • Broad experience working with big-data generated by high-throughput assays – next gen sequencing, HTS flow cytometric data, Multiplexed proteomics data a plus.
- • Excellent communication, data presentation and visualization skills
- • 5+ year of experience with strong oral and written communication skills that foster collaboration and teamwork.
- • Proficient in using high-level programming languages such as Python, R, Matlab, Java and Shell in a Linux environment.
- • Knowledge of current algorithms and technologies related to machine learning, predictive modeling or AI in biomedical research.
- • A successful track record in developing predictive models on clinical data, demonstrated by strong peer-review publications or new drug applications to regulatory agencies.
Compensation & Benefits
Codiak provides competitive compensation and benefits package that support and reward the contributions of each member of the team.
Apply TodayThose interested in joining the team effort at Codiak BioSciences to advance the nascent and exciting field of exosome technology into therapeutics with transformative potential are invited to email their CV.
Recent discoveries have demonstrated that exosomes derived from normal cells can act as a potent and safe delivery system for multiple therapeutic payloads. These small vesicles, which leave cells and travel throughout the body, can mediate dramatic effects in animal models of disease.
We are developing a broad platform for the delivery of macromolecules to the cytoplasm of diverse cells and tissues, to create a proprietary pipeline of novel, targeted medicines for diseases with high unmet medical need. The company’s technology exploits the natural propensity of exosomes to transmit macromolecule payloads between cells to create a pipeline of drugs across a broad range of diseases, including those associated with currently “undruggable” targets. While our initial focus is on oncology/immuno-oncology, this approach also offers significant potential in hematology, neurology and gene therapy and other therapy areas.
We are now producing drug candidate exosomes using the engExTM platform, our novel therapeutic engine for exosomes. We tailor exosomes to express molecules on their surfaces and/or deliver specific cargo inside. This affords us the flexibility for designing proprietary drug candidates; exosomes can be mixed and matched into rational and targeted combinations with the potential for a broad therapeutic platform.
As of December 2017, Codiak has raised a combined $168.5M in Series A-C financing. The company maintains partnerships with academic exosome labs and has multiple paths to clinical and commercial success through the breadth of the company’s research, strength of its IP position and proprietary innovation behind its production capabilities.
Codiak’s CEO and first employee Doug Williams, Ph.D., (former EVP of Biogen R&D, CEO of ZymoGenetics) espouses the belief that inspired employees create great science. Employees treat the company as if it was their own and report that there is “direct and respectful communication,” and “trust that teammates will do the right thing and never compromise integrity.”
Named one of 11 disruptive startups “on a do-or-die mission to launch new meds” by Endpoints News in January 2018, Codiak is in the heart of Boston’s biotechnology hub at 500 Technology Square in Cambridge, Massachusetts.
Codiak BioSciences is an Equal Opportunity Employer committed to a culturally diverse workforce. All qualified applicants will receive consideration for employment without regard to race; color; creed; religion; national origin; age; ancestry; nationality; marital, domestic partnership or civil union status; sex, gender, gender identity or expression; affectional or sexual orientation; disability; veteran or military status or liability for military status.